Targeted Therapies & Precision Oncology

Significant PR survival with Savolitinib + Osimertinib in with EGFR-Mutant,MET amplified NSCLC pts

Superior survival outcomes shown by Rybrevant + Lazcluze Combo as compared to Tagrisso in EGFR mutated NSCLC. The therapy also demonstrated quality-of-life benefits, marking it as a potential new standard of care.

🧠 AI & Diagnostics

AI Enhances HER2 Testing Accuracy: A multinational study revealed that artificial intelligence assistance improved pathologists’ accuracy in categorizing HER2 levels in breast cancer patients from 66.7% to 88.5%. This advancement could ensure more patients access HER2-targeted treatments like ENHERTU® (fam-trastuzumab deruxtecan-nxki) HCP

💊 Supportive Care Advances

Nplate Reduces Chemotherapy-Induced Thrombocytopenia: Amgen’s Nplate (romiplostim) was found to be highly effective in preventing chemotherapy-induced thrombocytopenia (CIT), enabling 84% of treated patients to continue full-dose chemotherapy without dose reductions, compared to 36% in the placebo group. This could transform clinical practices, as no FDA-approved treatments currently exist for CIT.

🧬 Gynecologic & Breast Cancer Breakthroughs

Relacorilant + Nab-Paclitaxel in Ovarian Cancer: The Phase III ROSELLA trial presented findings on the combination of relacorilant with nab-paclitaxel for patients with platinum-resistant ovarian cancer, indicating potential improvements in treatment outcomes.

SERENA-6 Study in Breast Cancer: This study explores using circulating tumor DNA to detect resistance and guide therapy changes before radiographic progression in breast cancer patients, potentially marking a paradigm shift in treatment strategy. Patients

🌐 Broader Trends & Themes

AI’s Expanding Role: Artificial intelligence is increasingly being integrated into oncology, enhancing diagnostics, treatment planning, and research efficiency.

Patient-centric campaigns highlight the importance of patient experiences and advocacy in cancer care.